CAR T-cell therapy works wonders for some cancer patients. For others, it is a death sentence. To make the revolutionary therapy work for more people, scientists must devise better ways to control it

The startup raised $40 million to target a class of GPCRs called Mas-related G-protein receptors, to treat neuroimmune and inflammatory conditions

The drug company will pay $1.6 billion to gain Armo’s IL-10 program

Frontal polymerization approach reduces energy use significantly

Joined by CRISPR luminaries Feng Zhang and J. Keith Joung, the Harvard chemist raises up to $87 million in funding

The start-up, based on the work of Broad Institute scientist Aviv Regev, has raised $65 million to develop therapies for cancer and autoimmune disease

El triclorofluorometano probablemente se origine en fábricas del este de Asia

Start-up wants to foster a quantum leap in molecular problem-solving

Listen as we visit the Smithsonian to learn how stable isotope analysis can reveal the stories behind skeletons

Strong demand and Chinese environment controls lead to robust earnings

With $40 million series A funding, the start-up will develop inhibitors of proteins that make chemical modifications to RNA

Chemical educator and Compound Interest blogger Andy Brunning explains the similarities and differences between the two bath products

On the brink of patient trials, genome-editing heavyweights and regulators meet to set up voluntary standards

Joined by CRISPR luminaries Feng Zhang and J. Keith Joung, the Harvard chemist raises up to $87 million in funding

Company expects to slim its home country head count by 600

Researchers are simultaneously shrinking mass specs and broadening their tandem capabilities

Dynamic boron-oxygen networks are key to the new material’s unusual properties

A new report from the Cancer Research Institute highlights the U.S. and China as cell therapy leaders

With so many ingredients on hand, can the oncology community figure out how to sensibly and efficiently combine checkpoint inhibitors with other drugs?

Private equity firm aims to assemble a specialty additives powerhouse

The startup is developing allosteric activators to increase levels of the vital metabolic molecule coenzyme A in pantothenate kinase-associated neurodegeneration

Chemical educator and Compound Interest blogger Andy Brunning wrings all the molecular details out of the popular goo

Flat, macrocyclic host captures fullerene guest with CH–π interactions

A new National Academies report names and classifies the kinds of biological weapons that could emerge from techniques like CRISPR gene editing and DNA synthesis

The early peek at data from a Phase I/II study excited families, physicians, and investors 

Treating roads with the wastewater may pollute the environment with radium and oil and gas compounds

French pharmaceutical services firm is latest to move into the U.S.

In confined spaces, water’s dielectric constant drops dramatically, according to new measurements

Treating roads with wastewater may pollute the environment with radium

The drug company is partnering with Calibr to develop universal CAR T-cells directed to different tumors via antibody switches